- Home
- MUJ vs CRMD Comparison
MUJ vs CRMD Comparison
Compare MUJ & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- CRMD
- Stock Information
- Founded
- MUJ 1998
- CRMD 2006
- Country
- MUJ United States
- CRMD United States
- Employees
- MUJ N/A
- CRMD N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- CRMD Health Care
- Exchange
- MUJ Nasdaq
- CRMD Nasdaq
- Market Cap
- MUJ 573.3M
- CRMD 973.3M
- IPO Year
- MUJ N/A
- CRMD 2010
- Fundamental
- Price
- MUJ $10.91
- CRMD $12.32
- Analyst Decision
- MUJ
- CRMD Strong Buy
- Analyst Count
- MUJ 0
- CRMD 7
- Target Price
- MUJ N/A
- CRMD $17.33
- AVG Volume (30 Days)
- MUJ 108.0K
- CRMD 2.3M
- Earning Date
- MUJ 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- MUJ 4.36%
- CRMD N/A
- EPS Growth
- MUJ N/A
- CRMD N/A
- EPS
- MUJ N/A
- CRMD 0.28
- Revenue
- MUJ N/A
- CRMD $82,553,827.00
- Revenue This Year
- MUJ N/A
- CRMD $238.38
- Revenue Next Year
- MUJ N/A
- CRMD $53.52
- P/E Ratio
- MUJ N/A
- CRMD $44.38
- Revenue Growth
- MUJ N/A
- CRMD N/A
- 52 Week Low
- MUJ $9.74
- CRMD $3.61
- 52 Week High
- MUJ $11.70
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- MUJ 53.88
- CRMD 42.94
- Support Level
- MUJ $10.78
- CRMD $12.14
- Resistance Level
- MUJ $10.86
- CRMD $17.43
- Average True Range (ATR)
- MUJ 0.07
- CRMD 0.80
- MACD
- MUJ 0.01
- CRMD -0.33
- Stochastic Oscillator
- MUJ 100.00
- CRMD 3.40
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.